Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout

Arthritis Care and Research

Volumn 47, Issue 4, 2002, Pages 356-360

  Perez Ruiz, Fernando ^a   Calabozo, Marcelo ^a   Pijoan, Jose I ^a   Herrero Beites, Ana M ^b   Ruibal, Ana ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b Hospital de Gorliz   (Spain)

Author keywords

Allopurinol; Benzbromarone; Gout; Gout suppressants; Tophus

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; BENZBROMARONE; URATE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL; DISSOLUTION; DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; URIC ACID BLOOD LEVEL; VELOCITY;

EID: 0037103137     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10511     Document Type: Article

References (30)

1. Milestones in the treatment of gout
2. Orderly arrayed deposit of urate crystals in gout suggest epitaxial formation
3. Osteoarthritis and crystal deposition diseases
4. Management of gout
5. The management of gout
6. Crystal-induced arthritis: An overview
7. Treatment of gout
8. How well have diagnostic tests and therapies for gout been evaluated?
9. Treatment of chronic gout: A new approach to an ancient disease
10. Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency
11. Allopurinol and gouty hyperuricemia: Efficacy of a single daily dose
12. Effects of pyrazinamide, probenecid, and benzobromaraone on renal excretion of oxypurinol
13. Treatment of primary gout: The present status
14. Should patients with interval gout be treated with urate lowering drugs?
15. An evidence based appraisal of the management of nontophaceous interval gout
16. Mobilization of gouty tophi by protracted use of uricosuric agents
17. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout
18. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout
19. Studies on the crystallization in relation to gout
20. Effect of single oral doses of benzbromarone on serum and urinary uric acid
21. Pharmacokinetic and clinical studies of a new uricosuric agent: Benzbromarone
22. Clinical evaluation of benzbromarone: A new uricosuric agent
23. Benzbromarone therapy in hyperuricemia; comparison with allopurinol and probenecid
24. Benzbromarone as a long-term uricosuric agent
25. The pathogenesis of gout
26. Studies of uric acid pool size and turnover rate
27. Isolation and quantification of serum uric acid by absorption chromatography
28. Uric acid metabolism in Cebus monkey
29. Uric acid metabolism in normal subjects and in gouty patients by chromatographic measurement of 14C-uric acid in plasma and urine
30. The treatment of hyperuricemia: Allopurinol and beyond